Business Wire

The newsfeed available here is provided by our content partner Business Wire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public. Business Wire is a subsidiary of the Warren Buffett Group Berkshire Hathaway.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
System-State: Number of processed items 35.500 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
Business Wire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
US2928121043
State: 01.04.2025 | 6PM
Do you already know our new terminal view? Click here.
FIGI: BBG012MBFQD7
ENFN
Enfusion, Inc.
GICS: - · Sector: Technology · Sub-Sector: Software - Application
NAME
Enfusion, Inc.
ISIN
US2928121043
TICKER
ENFN
MIC
XNYS
REUTERS
ENFN.N
BLOOMBERG
ENFN US
Mon, 03.03.2025       Enfusion
US2928121043

Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: Total revenue was $52.9 million, up 13.9% compared to the same period in the p...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Tue, 25.02.2025       Enfusion
US2928121043

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Enfusion, Inc. (NYSE: ENFN) to Clearwater Analytics for $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock is fair to Enfusion shareholders. Halper Sadeh encourages Enfusion shareholders to click here to learn more about their legal ri...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Tue, 14.01.2025       Enfusion
US2928121043

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Enfusion, Inc. (NYSE: ENFN) to Clearwater Analytics Holdings, Inc. (NYSE: CWAN). Under the terms of the proposed transaction, shareholders of Enfusion will receive $5.85 in cash and $5.40 in ...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Mon, 13.01.2025       Enfusion
US2928121043

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Enfusion, Inc. (“Enfusion” or “the Company”) (NYSE: ENFN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Enfusion board brea...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Mon, 13.01.2025       Enfusion
US2928121043

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Enfusion, Inc. (NYSE: ENFN) to Clearwater Analytics for $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock is fair to Enfusion shareholders. Halper Sadeh encourages Enfusion shareholders to click here to learn more about their legal ri...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Mon, 13.01.2025       Enfusion
US2928121043

Ademi LLP is investigating Enfusion (NYSE: ENFN) for possible breaches of fiduciary duty and other violations of law in its transaction with Clearwater. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In t...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Wed, 20.11.2024       Enfusion
US2928121043

Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced that Enfusion’s Chief Financial Officer, Brad Herring, and Chief Operating Officer, Neal Pawar, will participate at the following investor events: Wells Fargo 8th Annual TMT Summit on Tuesday, December ...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Mon, 04.11.2024       Enfusion
US2928121043

Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, has posted its third quarter 2024 financial results as part of its Q3 2024 Shareholder Letter which can be viewed by navigating to the Financials section of its Investor Relations website at http://ir.enfusion.com. 3Q24 ...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Thu, 10.10.2024       Enfusion
US2928121043

Enfusion, Inc. (“Enfusion”) (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, announced today the appointments of Arman Artuc to Head of Engineering and Jesper Cordes to Head of Client Services Americas. These additions to the leadership team reinforce the company’s position as a global leader in i...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Thu, 03.10.2024       Enfusion
US2928121043

Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced it will release its third quarter 2024 financial results before the U.S. financial markets open on Monday, November 4, 2024. Management will host a conference call and webcast that same morning at 8:30 AM ...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Wed, 04.09.2024       Enfusion
US2928121043

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. (“Enfusion” or “the Company”) (NYSE: ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclo...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Thu, 22.08.2024       Enfusion
US2928121043

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. (“Enfusion” or “the Company”) (NYSE: ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ENFN. ...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Wed, 14.08.2024       Enfusion
US2928121043

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. (“Enfusion” or “the Company”) (NYSE: ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ENFN. ...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Sat, 10.08.2024       Enfusion
US2928121043

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. (“Enfusion” or “the Company”) (NYSE: ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclo...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.

On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.